|drug860||Continuation of ACEi/ARB Wiki||0.33|
|drug1191||Enhanced hygiene measures Wiki||0.33|
|drug302||Assessment of ventilator-associated pneumonia criteria Wiki||0.33|
|drug3024||Scanning Chest X-rays and performing AI algorithms on images Wiki||0.33|
|drug1062||Discontinuation of ACEi/ARB Wiki||0.33|
|drug3234||Sterile Water for Injection Wiki||0.33|
|drug247||Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients Wiki||0.33|
|drug1864||Lovenox 40 MG in 0.4 mL Prefilled Syringe Wiki||0.33|
|drug2792||Rapid Pathogen Detection Wiki||0.33|
|drug397||Bacterial species isolated Wiki||0.33|
|drug3537||Ultrasound of the lower limbs Wiki||0.33|
|drug3104||Single Dose of Hydroxychloroquine Wiki||0.24|
|drug1672||Interferon Beta-1A Wiki||0.17|
|drug1842||Lopinavir / Ritonavir Wiki||0.15|
|drug884||Convalescent Plasma Wiki||0.06|
|D000077299||Healthcare-Associated Pneumonia NIH||0.33|
|D011024||Pneumonia, Viral NIH||0.11|
|D007251||Influenza, Human NIH||0.10|
|D017563||Lung Diseases, Interstitial NIH||0.09|
|D012141||Respiratory Tract Infections NIH||0.06|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
|D003141||Communicable Diseases NIH||0.02|
|D018352||Coronavirus Infections NIH||0.02|
There are 9 clinical trials
Lower Respiratory Tract infections are a common cause of admission to the intensive care unit. Children routinely receive antibiotics until the tests confirm whether the infection is bacterial or viral. The exclusion of bacterial infection may take 48 hours or longer for culture tests on biological samples to be completed. In many cases, the results may be inconclusive or negative if the patient has already received antibiotics prior to the sample being taken. A rapid assay to detect the most likely cause of infection could improve the speed with which antibiotic therapy is rationalised or curtailed. This study aims to assess whether a new genetic testing kit which can identify the presence of bacteria and viruses within hours rather than days is a feasible tool in improving antibiotic prescribing and rationalisation of therapy in critically ill children with suspected lower respiratory tract infection.
Description: Performance of novel pathogen detection assays compared to standard microbiology, in regard to sensitivity, specificity and likelihood ratiosMeasure: Performance of the novel pathogen detection assay Time: 3 years
Description: Time to reportable test resultsMeasure: Time to results Time: 3 years
Description: Where routine culture is negative, what proportion of tests have a positive detection using the novel assay?Measure: Negative cultures Time: 3 years
Description: Duration of therapy and number of antibiotic classes during paediatric intensive care unit admissionMeasure: Antibiotic therapy Time: 3 years
Description: Number of critically ill children requiring mechanical ventilation with COVID19 compared to those withoutMeasure: Prevalence of COVID19 in children admitted to PICU Time: 2 years
2019 new coronavirus (2019-nCoV) infected pneumonia, namely severe acute respiratory infection (SARI) has caused global concern and emergency. There is a lack of effective targeted antiviral drugs, and symptomatic supportive treatment is still the current main treatment for SARI. Vitamin C is significant to human body and plays a role in reducing inflammatory response and preventing common cold. In addtion, a few studies have shown that vitamin C deficiency is related to the increased risk and severity of influenza infections. We hypothize that Vitamin C infusion can help improve the prognosis of patients with SARI. Therefore, it is necessary to study the clinical efficacy and safety of vitamin C for the clinical management of SARI through randomized controlled trials during the current epidemic of SARI.
Description: days without ventilation support during 28 days after patients' enrollmentMeasure: Ventilation-free days Time: on the day 28 after enrollment
Description: wether the patient survivesMeasure: 28-days mortality Time: on the day 28 after enrollment
Description: days of the patients staying in the ICUMeasure: ICU length of stay Time: on the day 28 after enrollment
Description: the rate of CPRMeasure: Demand for first aid measuments Time: on the day 28 after enrollment
Description: days of using vasopressorsMeasure: Vasopressor days Time: on the day 28 after enrollment
Description: P O2/Fi O2 which reflects patients' respiratory functionMeasure: Respiratory indexes Time: on the day 10 and 28 after enrollment
Description: Ecmo or ventilatorMeasure: Ventilator parameters Time: on the day 10 and 28 after enrollment
Description: Acute Physiology and Chronic Health EvaluationMeasure: APACHE II scores Time: on the day 10 after enrollment
Description: Sepsis-related Organ Failure AssessmentMeasure: SOFA scores Time: on the day 10 after enrollment
Serious Pneumonia and Critical Pneumonia caused by the 2019-nCOV infection greatly threats patients' life, UC-MSCs treatment has been proved to play a role in curing multiple diseases. And this study is conducted to find out whether or not it will function in 2019-nCOV infection Pneumonia.
Description: partial arterial oxygen pressure (PaO2) / oxygen concentration (FiO2)Measure: Oxygenation index Time: on the day 14 after enrollment
Description: whether the patient survivesMeasure: 28 day mortality Time: on the day 28 after enrollment
Description: days of the patients in hospitalMeasure: Hospital stay Time: up to 6 months
Description: whether or not the 2019-nCoV antibody is positiveMeasure: 2019-nCoV antibody test Time: on the day 7,14,28 after enrollment
Description: whether or not the 2019-nCoV nucleic acid test is positiveMeasure: 2019-nCoV nucleic acid test Time: on the day 7,14,28 after enrollment
Description: whether lung imaging examinations show the improvement of the pneumoniaMeasure: Improvement of lung imaging examinations Time: on the day 7,14,28 after enrollment
Description: counts of white blood cell in a litre of bloodMeasure: White blood cell count Time: on the day 7,14,28 after enrollment
Description: counts of lymphocyte in a litre (L) of bloodMeasure: Lymphocyte count Time: on the day 7,14,28 after enrollment
Description: procalcitonin in microgram(ug)/LMeasure: Procalcitonin Time: on the day 7,14,28 after enrollment
Description: IL-2 in picogram(pg)/millilitre(mL)Measure: interleukin(IL)-2 Time: on the day 7,14,28 after enrollment
Description: IL-4 in pg/mLMeasure: IL-4 Time: on the day 7,14,28 after enrollment
Description: IL-6 in pg/mLMeasure: IL-6 Time: on the day 7,14,28 after enrollment
Description: IL-10 in pg/mLMeasure: IL-10 Time: on the day 7,14,28 after enrollment
Description: TNF-α in nanogram(ng)/LMeasure: tumor necrosis factor(TNF)-α Time: on the day 7,14,28 after enrollment
Description: γ-IFN in a thousand unit (KU)/LMeasure: γ-interferon(IFN) Time: on the day 7,14,28 after enrollment
Description: CRP in microgram（μg）/LMeasure: C-reactive protein(CRP) Time: on the day 7,14,28 after enrollment
Description: counts of CD4+ T-Lymphocytopenia in litreMeasure: CD4+ T-Lymphocytopenia Time: on the day 7,14,28 after enrollment
Description: counts of CD8+ T-Lymphocytopenia in a litreMeasure: CD8+ T-Lymphocytopenia Time: on the day 7,14,28 after enrollment
Description: counts of NK in a litreMeasure: natural killer cell(NK) Time: on the day 7,14,28 after enrollment
This project aims to use artificial intelligence (image discrimination) algorithms, specifically convolutional neural networks (CNNs) for scanning chest radiographs in the emergency department (triage) in patients with suspected respiratory symptoms (fever, cough, myalgia) of coronavirus infection COVID 19. The objective is to create and validate a software solution that discriminates on the basis of the chest x-ray between Covid-19 pneumonitis and influenza
Description: Number of participants with pneumonitis on Chest X-Ray and COVID 19 positiveMeasure: COVID-19 positive X-Rays Time: 6 months
Description: Number of participants with pneumonitis on Chest X-Ray and COVID 19 negativeMeasure: COVID-19 negative X-Rays Time: 6 months
National multicentric observational retrospective case-control study comparing the relative frequency of the various microorganisms responsible for VAP in patients infected or not by SARS-CoV-2 and their resistance to antibiotics.
The 2019 outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID 19), which originated in Wuhan, China, has become a major concern all over the world. Convalescent plasma or immunoglobulins have been used as a last resort to improve the survival rate of patients with SARS whose condition continued to deteriorate despite any attempted treatment.. Moreover, several studies showed a shorter hospital stay and lower mortality in patients treated with convalescent plasma than those who were not treated with convalescent plasma. Evidence shows that convalescent plasma from patients who have recovered from viral infections can be used effectively as a treatment of patients with active disease. The use of solutions enriched of antiviral antibodies has several important advantages over the convalescent plasma including the high level of neutralizing antibodies supplied. Plasma-exchange is expensive and requires large volumes of substitution fluid. Albumin is better tolerated and less expensive, but exchanges using albumin solutions increase the risk of bleeding because of progressive coagulation factor depletion. With either albumin or fresh frozen plasma, increasing the risk of cardiovascular instability in the plasma donor and in the recipient, which can be detrimental in a critically ill patient with COVID 19 pneumonia. The aforementioned limitations of plasma therapy can be overcome by using selective apheresis methods, such as double-filtration plasmapheresis (DFPP).DFPP is a modality of plasma purification that performs an initial plasma separation from blood, and the subsequent separation of specific molecules, on the basis of their specific molecular weight (cut-off), by using a fractionation filter. The Fractionation Filter 2A20, because of its membrane sieving cut-off, retains larger molecules and returns plasma along with smaller molecules to the circulation, including the major part of the albumin. The selection of the membrane 2A20 is related to the appropriate Sieving Coefficient for IgG that allows to efficiently collect antibodies from patients which are recovered from COVID-19, with negligible fluid losses and limited removal of albumin. The total amount of antibodies obtained during one DFPP session exceeds by three to four times the total amount provided to recipients with one unit of plasma obtained during one plasma-exchange session from one COVID-19 convalescent donor. This should result in more effective viral inhibition and larger benefit for the patient achieved with one unit of enriched immunoglobulin solution obtained with DFPP than with one unit of plasma obtained with plasma exchange. These observations provide the background for a pilot study aimed to explore whether the infusion of antibodies obtained with one single DFPP procedure from voluntary convalescent donors could offer an effective and safe therapeutic option for critically ill patients with severe coronavirus (COVID-19) pneumonia requiring mechanical ventilation.
Description: Marker of complement activation in plasma.Measure: C5a concentration Time: Changes from before Ig administration, one day and one week after Ig administration and every week after discharge from the intensive care unit through study completion, an average of 6 months.
Description: Marker of complement activation in plasma.Measure: C3a concentration Time: Changes from before Ig administration, one day and one week after Ig administration and every week after discharge from the intensive care unit through study completion, an average of 6 months.
Description: Marker of complement activation in plasma.Measure: Serum C5b-9 concentration Time: Changes from before Ig administration, one day and one week after Ig administration and every week after discharge from the intensive care unit through study completion, an average of 6 months.
A previous study showed a high incidence of ventilator-associated pneumonia to multidrug resistant pathogens in our ICU. That has been related to lack of compliance to hand hygiene among health care providers in ou ICU.
Description: Incidence of MDR bacteria in endotracheal aspiratesMeasure: MDR pathogens in endotracheal aspirates Time: 1 year
Description: Incidence of microorganisms in endotracheal aspiratesMeasure: Microorganisms in endotracheal aspirates Time: 1 year
The aim of this study is to determine the risk factors for development of ventilator-associated pneumonia (VAP) and to identify the prognostic factors of VAP among Coronavirus Disease 2019 (CoViD-19) patients. We hypothesized that CoViD-19 serves as a high risk factor for the development of VAP and it affects clinical outcome measures negatively.
A Respiratory infection with the SARS-CoV2 virus is associated with a major risk of viral pneumonia that can lead to respiratory distress requiring resuscitation. In the most severe forms, it may require mechanical ventilation or even lead to an acute respiratory distress syndrome with a particularly poor prognosis. The SARS-CoV2 is a single-stranded RNA virus of positive polarity and belongs to the beta genus of Coronaviruses. SARS-CoV2 is responsible for the third epidemic in less than twenty years secondary to a Coronavirus (SARS-CoV then MERS-CoV) and if the mortality associated with it is lower than that of previous strains, notably MERS-CoV, its spread is considerably big. As a result, the number of patients developing respiratory distress requiring invasive mechanical ventilation is high, with prolonged ventilation duration in these situations
Description: Establishing a biobank of the bacterial agents responsible for nosocomial pneumonia acquired under mechanical ventilation in order to: better understand the particularities of the bacteria responsible and obtain the "clinical" strains for in vitro studies that will be carried out secondarily.Measure: Research of the bacteria responsible for nosocomial pneumonia Time: 6 months
Description: Evaluation of the adhesion properties to the bronchial epithelium (LPS peculiarities of Gram-negative bacteria, the interaction with the virus in in vitro models and the different molecules of interest in the collected bronchial secretions).Measure: Additional evaluations to the study Time: 6 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports